



**Prof. Ronit Satchi-Fainaro, Ph.D.** is a Full Professor at Tel Aviv University, where she is head of the Cancer Research & Nanomedicine Laboratory, Director of the TAU Kahn 3D BioPrinting Initiative, Director of Cancer Biology Research Center and its 18-affiliated hospitals and holds the Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies. She served as Chair of the Department of Physiology & Pharmacology, as President of the Israeli Controlled Release Society (CRS), and Chair of IACUC. She received her BPharm from the Hebrew University in Jerusalem in 1995 and her PhD (*Summa Cum Laude*) in Polymer Chemistry and Cancer Nanomedicine from the University of London in 1999 with Ruth Duncan. She then spent four years as Postdoctoral Fellow at Harvard University and Children's Hospital Boston, working with Judah Folkman on Vascular and Cancer Biology. In 2003, she was appointed Instructor in Surgery at Boston Children's Hospital and Harvard Medical School. She joined Tel Aviv University in 2006. She has been a Visiting professor at Harvard Medical School since 2007 and at The University of Lisbon since 2019. She serves on the Board of Directors of Teva Pharmaceutical Industries, is a member of 8400-The Health network, and a member of Scientific Advisory Boards (SAB) of CAS- a division of the American Chemical Society (ACS), The Blavatnik Center for Drug Discovery, Israel Cancer Association, Hospital Universitari VHIR, MultiMedica Research Hospital Milan, University of Lisbon, Rothschild and Fulbright Fellowships Committees, several VCs, biotech companies and editorial boards of scientific journals. Her multidisciplinary research laboratory focuses on basic research elucidating the mechanisms underlying the switch from cancer dormancy leading to the discovery of new molecular targets to interrupt tumor-host interactions. Her approach is followed by the design of targeted molecules integrating engineering, biology, chemistry, medicine, bioinformatics, CAAD, and nanotechnology to guide drugs into pathological sites. Throughout, she has maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. To that end, her research led to the identification of P-selectin as a key regulator of brain cancers. This finding led to an ongoing 30-patient clinical trial evaluating a P-selectin inhibitor as a therapy for glioblastoma and brain metastasis patients. She also developed a platform for 3D-bioprinted cancer models that is being exploited in an 80-patient clinical trial for personalized therapy of multiple cancer types. This technology won the 3D Printing Industry Award - Medical Application of the Year. Satchi-Fainaro has authored over 160 publications, 13 book chapters, edited 2 books, is named inventor on 95 patents, some of which were licensed to Pharmaceutical and Biotech companies, founded 3 companies, and has delivered over 600 plenary and invited lectures worldwide. Her students are pursuing careers in academia, industry, and government. She is actively engaged in translational research with several industry partners and in science outreach. She was awarded numerous prestigious grants and prizes, among them Fulbright, Rothschild, Wingate, Alon, Young Investigator Award of the EACR, JULUDAN Prize for the Advancement of Technology in Medicine, Teva Pharmaceutical Industries Founders Award for the Discovery of new molecular mechanisms and targets that would lead to new therapeutic approaches, CRS Translational Research Award, 2020 Youdim Family Prize for Excellence in Cancer Research, 2020 Kadar Family Award for Outstanding Research, 2020 Michael Bruno Memorial Award, 2020 Humboldt Foundation Bessel Research Prize, 2021 Salisbury Award for Entrepreneurial Translational Research by the National Foundation for Cancer Research, 2021 AIM-HI accelerator fund Women's Venture Competition-People's Choice Award and the 2024 Tenne Family Prize for Nanoscale Sciences. She was elected Fellow of the American Institute of Medical and Biological Engineers (AIMBE) in 2023, and to the 2022 CRS College of Fellows recognizing an exceptional individual who has made outstanding and sustained contributions to the field of delivery science and technology over a minimum of 10 years. Her scientific achievements were acknowledged numerous times by inclusion in honorary lists by leading magazines (2022 Power Women List Forbes, 2019 Globes Woman of the Year, named one of Israel's Top 40 under 40 by The Marker, and by the Calcalist, one of 20 most promising Israelis by Yediot Aharonot, and Allgemeiner's top 100 people positively influencing Jewish life). She was elected the 2019 Chair, Gordon Research Conference on Cancer Nanotechnology, was awarded

the 2018 Israel Cancer Research Fund Professorship, represented Israel at the 2016 Biennale in Venice, building an installation on the Influence of Medicine on Architecture, and was awarded 4 times the La Caixa Bank Foundation grants, ERC Consolidator, ERC Advanced, 2 ERC PoC, and EIC Grants.